Clinical Trial Update: Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for letermovir as primary prophylaxis of cytomegalovirus infection after R+HID-HSCT.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection
• Peripheral Blood Cmv Activation

Drugs mentioned

• Letermovir (letermovir)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation | Phase 4 | Status: UNKNOWN